

Announcement of April 11, 2025

## BB Biotech AG concludes its share buyback program

On April 11, 2025, BB Biotech AG concluded the share buyback program it had initiated on April 13, 2022. During this period, 250 750 registered shares were repurchased via a second trading line for the purpose of capital reduction.

### **For further information:**

Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

### **Head Investment Management Team BB Biotech**

Dr. Christian Koch

### **Investor Relations**

[ir@bbbiotech.com](mailto:ir@bbbiotech.com)

Claude Mikkelsen, [cmi@bellevue.ch](mailto:cmi@bellevue.ch)

### **Media Relations**

Tanja Chicherio, [tch@bellevue.ch](mailto:tch@bellevue.ch)

**[www.bbbiotech.com](http://www.bbbiotech.com)**

### **Company profile**

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

### **Disclaimer**

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech AG, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech AG and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech AG and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.